Detalhe da pesquisa
1.
Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study.
Haematologica
; 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38572554
2.
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia.
Am J Hematol
; 93(9): 1136-1141, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30028037
3.
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Am J Hematol
; 91(8): 800-5, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27169385
4.
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Blood
; 121(23): 4655-62, 2013 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-23613521
5.
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.
Lancet Haematol
; 6(1): e29-e37, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30545576
6.
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Clin Cancer Res
; 21(12): 2704-14, 2015 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25724525
7.
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis.
Leuk Lymphoma
; 51(2): 269-74, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20038218
8.
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
J Clin Oncol
; 27(32): 5418-24, 2009 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19826111
9.
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Cancer
; 110(9): 2012-8, 2007 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17849460